Clinical Trial

Evaluation of Blood Loss After Cesarean Delivery Via US Compared to Standard Care

Recruiting
View on ClinicalTrials.gov →
Summary
Postpartum hemorrhage and anemia are considered a major health concern due to their impact on maternal morbidity and mortality, quality of life, and maternal cognitive and emotional functioning after delivery, which are particularly important during the critical period of mother-child bonding. Hemoglobin levels in the first 24 hours after delivery do not reflect the lowest point (nadir). The postpartum nadir occurs 48-72 hours after delivery due to the initial redistribution of plasma volume. The aim of this study was to examine whether postpartum ultrasound examination precedes laboratory test results in the diagnosis of anemia due to blood loss after cesarean section.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05-01 -> 2027-05-01 2026-06-17
minor Completion pushed: 2026-06-01 -> 2027-06-01 2026-06-17
Trial Details
NCT Number NCT06963047
Lead Sponsor Holy Family Hospital, Nazareth, Israel
Conditions Postpartum Period
Enrollment 276 participants
Start Date 2025-05-08
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-16